Hong Kong Stock Anomaly | He Yue-B(02256) rises over 9% again Beigema Global Phase III MANEUVER Study Results Featured in The Lancet

LootboxPhobia · 2026-03-10T06:25:07+00:00

HeYu-B rises over 9% again, currently trading at HKD 12.91. The company announced that the Phase III study results of its CSF-1R inhibitor Bejeimai have been published in The Lancet, marking recognition of this innovative therapy in the international academic community.

LootboxPhobia

2026-03-10 06:25:07

Abstract generation in progress

Tongtong Finance APP learns that HeYu-B (02256) rose more than 9% again. As of press time, it increased by 8.76%, trading at HKD 12.91, with a turnover of HKD 21.9969 million.

On the news front, HeYu Pharmaceuticals announced that the global multi-center Phase III MANEUVER study results of its self-developed, new, oral, highly selective, and efficient small-molecule CSF-1R inhibitor Bejimai (Pimodipine Hydrochloride Capsules, ABSK021) were officially published in the international medical journal The Lancet on March 5. This publication marks an important milestone for HeYu Pharmaceuticals’ innovative therapy in terms of clinical research quality, data integrity, and international academic recognition.

View Original

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.